Scarica l'app Stockscreener
39.65
0.89%
0.35
Pre-mercato:
39.85
0.20
+0.50%
Precedente Chiudi:
$39.30
Aprire:
$40.4
Volume 24 ore:
1.71M
Relative Volume:
1.31
Capitalizzazione di mercato:
$2.81B
Reddito:
-
Utile/perdita netta:
$-218.28M
Rapporto P/E:
-11.07
EPS:
-3.5803
Flusso di cassa netto:
$-186.55M
1 W Prestazione:
-4.87%
1M Prestazione:
-7.23%
6M Prestazione:
+81.05%
1 anno Prestazione:
+38.64%
Intervallo 1D:
$39.25
$40.95
Intervallo di 1 settimana:
$38.85
$42.47
Portata 52W:
$18.53
$56.05
Vera Therapeutics Inc Stock (VERA) Company Profile
Nome
Vera Therapeutics Inc
Settore
Industria
Telefono
650-770-0077
Indirizzo
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Compare VERA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
39.65 | 2.79B | 0 | -218.28M | -186.55M | -3.5803 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-16 | Iniziato | BofA Securities | Buy |
| 2025-08-04 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-05-05 | Ripresa | H.C. Wainwright | Buy |
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2025-01-28 | Iniziato | Goldman | Buy |
| 2024-11-21 | Iniziato | Wells Fargo | Overweight |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-01-25 | Iniziato | Oppenheimer | Outperform |
| 2024-01-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-12-18 | Iniziato | Raymond James | Outperform |
| 2023-11-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-08-16 | Iniziato | Guggenheim | Buy |
| 2023-01-04 | Downgrade | Jefferies | Buy → Hold |
| 2023-01-04 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-07-12 | Iniziato | JP Morgan | Overweight |
| 2022-05-02 | Iniziato | H.C. Wainwright | Buy |
| 2022-04-19 | Iniziato | Wedbush | Outperform |
Mostra tutto
Vera Therapeutics Inc Borsa (VERA) Ultime notizie
Vera Therapeutics Files BLA for Atacicept in IgAN, Target Action Date July 7, 2026 - Intellectia AI
Vera Therapeutics, Inc. (VERA) Stock Analysis: 94.88% Potential Upside Signals Compelling Opportunity - DirectorsTalk Interviews
HC Wainwright Issues Positive Forecast for Vera Therapeutics (NASDAQ:VERA) Stock Price - MarketBeat
VERA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Vera Therapeutics Raises $261M in Public Offering at $42.50 per Share - Intellectia AI
Positive Phase 3 IgA Data and FDA Priority Review Could Be A Game Changer For Vera Therapeutics (VERA) - Sahm
Trading Systems Reacting to (VERA) Volatility - Stock Traders Daily
Key facts: Vera Therapeutics submits atacicept BLA; posts $299.6M loss - TradingView
Wedbush Raises Price Target on Vera Therapeutics to $35 From $33, Keeps Neutral Rating - marketscreener.com
Does FDA Priority Review And Phase 3 Win For Atacicept Redefine The Bull Case For Vera (VERA)? - Yahoo Finance
VERA Should I Buy - Intellectia AI
Atacicept progress puts Vera Therapeutics (NASDAQ: VERA) at key FDA milestone - Stock Titan
Vera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
VERA: FDA priority review and strong cash reserves set the stage for atacicept's 2026 launch - TradingView
BRIEF-Vera Therapeutics FY EPS USD -4.66 Vs. IBES Estimate USD -4.55 - TradingView
Vera Therapeutics (VERA) widens 2025 loss as atacicept wins FDA priority review - Stock Titan
Biotech bets on kidney drug: Vera raises $800M after $299.6M loss - Stock Titan
Vera Therapeutics (NASDAQ:VERA) SVP Sells $130,851.66 in Stock - MarketBeat
Vera Therapeutics (NASDAQ:VERA) Insider Laurence Matthew Skelton Sells 1,582 Shares - MarketBeat
Insider Selling: Vera Therapeutics (NASDAQ:VERA) Insider Sells 2,187 Shares of Stock - MarketBeat
Insider Selling: Vera Therapeutics (NASDAQ:VERA) COO Sells 2,579 Shares of Stock - MarketBeat
Vera Therapeutics (VERA) CEO executes 16,925-share tax sell-to-cover trade - Stock Titan
Vera Therapeutics (VERA) CCO sells 1,582 shares in RSU tax sale - Stock Titan
Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results - Bitget
Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Vera Therapeutics to Participate at Upcoming Investor Conferences - GlobeNewswire
Vera Therapeutics, Inc. (VERA) Stock Analysis: Exploring a 78.68% Potential Upside in Biotechnology - DirectorsTalk Interviews
Broker files Rule 144 to sell 1,800 VERA shares (NASDAQ: VERA) - Stock Titan
Morgan Stanley to sell 2,600 VERA shares (NASDAQ: VERA) under Rule 144 - Stock Titan
VERA (NASDAQ: VERA) notice of 5,700-share sale via Form 144 - Stock Titan
Morgan Stanley Smith Barney reports sale of 2,500 VERA shares (VERA) - Stock Titan
[144] Vera Therapeutics, Inc. SEC Filing - Stock Titan
VERA (NASDAQ: VERA) files Rule 144 sale notice for 16,600 shares - Stock Titan
Options Flow: How cyclical is Vera Therapeutics Incs revenue streamBear Alert & Free Community Consensus Stock Picks - baoquankhu1.vn
Assessing Vera Therapeutics (VERA) Valuation After Atacicept Phase 3 Success And Analyst Downgrade - Sahm
Vera Therapeutics: Hold Rating Based On Potential For Atacicept In IgAN (Rating Downgrade) - Seeking Alpha
Published on: 2026-02-20 18:05:40 - mfd.ru
Analysts bullish on Vera Therapeutics (VERA) amid new commercial chief appointment - MSN
Analysts Bullish on Vera Therapeutics (VERA) Amid New Commercial Chief Appointment - Insider Monkey
Death Cross: What is the earnings history of Vera Therapeutics Inc2025 Trading Recap & Fast Entry High Yield Tips - baoquankhu1.vn
Vera Therapeutics (VERA) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Panic Selling: Should I buy Vera Therapeutics Inc stock nowWeekly Trade Recap & High Accuracy Buy Signal Tips - baoquankhu1.vn
Why Vera Therapeutics, Inc. (VERA) Skyrocketed On Monday - MSN
T. Rowe Price holds 7.7% of Vera Therapeutics (VERA) common stock - Stock Titan
How Vera Therapeutics Inc. (VERA) Affects Rotational Strategy Timing - Stock Traders Daily
Atacicept’s Potential Approval Drives Favorable Views on Vera Therapeutics (VERA) - Yahoo Finance
Atacicept's Potential Approval Drives Favorable Views on Vera Therapeutics (VERA) - Finviz
Vera Therapeutics Reveals Inducement Grants in Accordance with Nasdaq Listing Rule 5635(c)(4) - Intellectia AI
B of A Securities Begins Coverage of Vera Therapeutics with a Buy Rating and Sets Price Target at $48 - Intellectia AI
17 Biotechnology Stocks with More Than 50% Upside - Insider Monkey
Breakout Watch: What is Vera Therapeutics Incs debt to equity ratioPortfolio Update Summary & Community Trade Idea Sharing - baoquankhu1.vn
Vera Therapeutics Inc Azioni (VERA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Vera Therapeutics Inc Azioni (VERA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Young Joseph R | SVP, FINANCE, CHIEF ACCT OFFCR |
Feb 23 '26 |
Sale |
41.98 |
3,117 |
130,864 |
64,722 |
| Grant Sean | CHIEF FINANCIAL OFFICER |
Feb 23 '26 |
Sale |
41.98 |
4,949 |
207,778 |
114,181 |
| Fordyce Marshall | PRESIDENT AND CEO |
Feb 23 '26 |
Sale |
41.98 |
16,925 |
710,578 |
257,163 |
| JOHNSON DAVID LEE | Chief Operating Officer |
Feb 23 '26 |
Sale |
41.98 |
2,579 |
108,276 |
45,727 |
| Turner William D. | Chief Regulatory Officer |
Feb 23 '26 |
Sale |
41.98 |
2,187 |
91,819 |
45,313 |
| Skelton Laurence Matthew | Chief Commercial Officer |
Feb 23 '26 |
Sale |
41.98 |
1,582 |
66,419 |
64,218 |
0.11%
6.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):